Nicole A. Doria‐Rose

The paper identifies distinct follicular helper CD4 T cell programming in HIV-positive individuals who produce broadly neutralizing antibodies, linking it to improved B cell follicle architecture and reduced suppressor cells.

This paper develops updated HIV-1 pseudovirus panels to better detect and assess B cell lineages with potential to produce broadly neutralizing antibodies against contemporary HIV-1 variants.

The paper identifies shared maturation pathways of V3-glycan broadly neutralizing antibody lineages in humans and rhesus macaques, revealing convergent mutations and evolution patterns.

This study designs a dual-epitope vaccine targeting HIV-1 Env's fusion peptide and V2 apex, showing it elicits neutralizing antibodies against both sites in rhesus macaques.

The paper identifies a new broadly neutralizing antibody, 04_A06, with high potency and breadth against HIV-1 strains, showing potential for prevention and therapy.

BRAVE predicts HIV-1 resistance to 33 bNAbs using a Random Forests classifier with a protein language model, outperforming existing tools in accuracy and other metrics.

This study isolates and characterizes V2 apex-directed neutralizing antibodies from SHIV-infected macaques, revealing structural and genetic features that enable broad neutralization.

This paper introduces a high-throughput method for screening antibody neutralization using droplet arrays, demonstrating scalable functional antibody data collection against viral diseases.

The paper develops machine learning classifiers to predict HIV-1 resistance to 33 neutralizing antibodies with 96% accuracy using clinical isolates.

The paper analyzes HIV-1 broadly neutralizing antibodies to classify epitopes and identify potential vaccine candidates based on structural and immunological features.